BIRMINGHAM, Ala., May 2, 2023 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will participate in the BofA Securities 2023 Healthcare Conference being held in Las Vegas May 9-11, 2023.
Encompass Health's Executive Vice President and Chief Financial Officer Doug Coltharp will present during a fireside chat on Tuesday, May 9, 2023, at 8 a.m. PT.
The presentation will be webcast live and available at http://investor.encompasshealth.com.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 157 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Media Contact
Casey Winger | 205 970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact
Mark Miller | 205 970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$103.35 |
Daily Change: | 0.35 0.34 |
Daily Volume: | 986,848 |
Market Cap: | US$10.410B |
December 18, 2024 November 04, 2024 October 28, 2024 August 05, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load